
Mezzion Pharma Co.,Ltd.
Share · KR7140410002 (XKOS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Mezzion Pharma Co.,Ltd.
No Price
Closing Price XKOS 30.04.2026:
90.000,00 KRW
30.04.2026 01:39
Current Prices from Mezzion Pharma Co.,Ltd.
| Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
|---|---|---|---|---|---|
KOSDAQ |
140410.KQ
|
KRW
|
30.04.2026 01:39
|
90.000,00 KRW
| -6.000,00 KRW
-6,25 %
|
Invested Funds
The following funds have invested in Mezzion Pharma Co.,Ltd.:
Fund | Vol. in million 137,39 | Percentage (%) 0,13 % |
Fund | Vol. in million 32,63 | Percentage (%) 0,01 % |
Fund | Vol. in million 165,20 | Percentage (%) 0,01 % |
Company Profile for Mezzion Pharma Co.,Ltd. Share
Mezzion Pharma Co., Ltd. engages in the development, production, and licensing of pharmaceutical products. Its products include erectile dysfunction, benign prostatic hyperplasia, and fontan therapeutic drugs. The company was founded by Park, Dong-Hyun on September 25, 2002 and is headquartered in Seoul, South Korea.
Company Data
Name Mezzion Pharma Co.,Ltd.
Company Mezzion Pharma Co.,Ltd.
Website
http://www.mezzion.co.kr
Primary Exchange
KOSDAQ
ISIN KR7140410002
Asset Class Share
CEO Dong-Hyun Park
Market Capitalization 2.918 Mrd.
Currency KRW
Employees -
IPO Date 2012-01-20
Dividends from 'Mezzion Pharma Co.,Ltd.'
| Ex-Date | Dividend per Share |
|---|---|
| 27.12.2012 | 75,00 KRW |
Stock Splits
| Date | Split |
|---|---|
| 05.04.2022 | 3:1 |
Ticker Symbols
| Name | Symbol |
|---|---|
| KOSDAQ | 140410.KQ |
More Shares
Investors who hold Mezzion Pharma Co.,Ltd. also have the following shares in their portfolio:

